Special Announcement - Now Enrolling for FDA Approved Stem Cell Study
Dr. Mitchell Sheinkop has completed training and is credentialed for the first of its kind FDA approved stem cell clinical trial for knee arthritis. Our clinic is now enrolling patients in this trial. Contact us at 312-475-1893 for details. Click here to learn more.
Dr. Mitchell Sheinkop Co-Authors Article Published in the International Journal of Recent Scientific Research

Dr. Mitchell Sheinkop Co-Authors Article Published in the International Journal of Recent Scientific Research

This excerpt is taken from the full article, which can be read here. Copyright © Mitchell B Sheinkop and Maxwell Dordevic,2019,

Abstract

This case report will introduce the concept of using an acellular mesenchymal stem cell (MSC) derived extracellular vesicle isolate product (EVIP) containing active growth factors (GFs) and exosomes to treat hip osteoarthritis (OA) as well as the rationale of why acellular may replace all current cellular biologic therapies both autogenous and allogeneic presently in use.

Excerpt

INTRODUCTION Hip osteoarthritis (OA) has demonstrated, in both cadaver and radiographic studies, to affect up to 55 million patients over the age of 60.1 Patients with hip OA have pain, crepitus, loss of motion, and decreased ability to weight bear or ambulate. Limiting the ability to ambulate severely impairs activities of daily living. The nonsurgical treatments for hip OA according to the American Academy of Orthopedic Surgeons (AAOS),include weight loss, gentle exercise, and the use of non-steroidal anti-inflammatory medications. The surgical treatment for hip OA is total hip arthroplasty (THA).2 The AAOS does not recommend hip arthroscopy or the use of any Hyaluronic Acid injections. Over the last few years, it has become increasingly understood by researchers and clinicians that the clinical efficacy of utilizing mesenchymal stem cells (MSCs) to treat osteoarthritis (OA) is not dependent on the cells differentiating into articular cartilage but entirely on their paracrine release of growth factors (GFs) and exosomes. Living MSCs are not required to accomplish the release of GFs and exosomes into an arthritic joint. This case report will introduce the concept of using an acellular MSC derived extracellular vesicle isolate product(EVIP) containing active growth factors and exosomes to treat hipOAas well as the rationale of why acellular may replace all current cellular biologic therapies both autogenous and allogeneic presently in use.

MATERIALS AND METHODS This is a case report of an EVIP injection for the treatment of hip osteoarthritis. OA is defined by swelling, pain, and stiffness in the hipjoint. Symptoms are typically worsened by weight bearing and ambulation.Radiographs and MRI scanning wereused tograde osteoarthritis of the hip joint from one to four using the Kellgen-Lawrence scale.12 The patient is a 63-year-old retired Chicago Fireman. He presented with increasing pain in the left groin and a progressive loss of ability to continue his daily health club fitness routine. He experienced a progressive loss of hip mobility.MRI scanning and radiographs of the left hip joint were compatible with Kellgren-Lawrence Grade 3 osteoarthritic changes of the left hip joint. On physical examination, he had an antalgic limp and a positive Trendelenburg sign. Passive ROM of the hip joint was associated with the reproduction of severe groin pain, crepitus, and a loss of internal rotation. The patient had a BMI of 27. NSAIDs had failed to provide adequate pain relief. The patient was seriously considering total hip arthroplasty. In an attempt to avoid surgery, he elected to have an injection of an EVIP containing active GFs and exosomes into his hip.

Read the full article at here.

Mitchell B Sheinkop and Maxwell Dordevic.2019, Intra-Articular Injection of An Extracellular Vesicle Isolate Product to Treat Hip Osteoarthritis. Int J Recent Sci Res. 10(12), pp. 36230-36232. DOI: http://dx.doi.org/10.24327/ijrsr.2019.1012.4884

Tags: , , ,

Pin It on Pinterest